Atara Biotherapeutics Balance Sheet Health
Financial Health criteria checks 2/6
Atara Biotherapeutics has a total shareholder equity of $-90.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $142.7M and $233.2M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$67.19m |
| Equity | -US$90.54m |
| Total liabilities | US$233.25m |
| Total assets | US$142.71m |
Recent financial health updates
Recent updates
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Nov 06
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Sep 06Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry
Jul 21Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy
Jul 03New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
May 14Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive
May 11Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
Feb 06Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely
Oct 17Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive
May 18Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)
Feb 13Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%
Nov 22EMA panel backs approval of Atara's Ebvallo for transplant complication
Oct 14Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre
Sep 28Financial Position Analysis
Short Term Liabilities: ATRA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: ATRA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: ATRA is debt free.
Reducing Debt: ATRA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATRA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ATRA has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 2.1% each year.